Answers are grounded in this paper and cite their sources.
Ketamine has recently attracted considerable attention for its rapid effects on patients with major depressive disorder, including treatment-resistant depression (TRD). Despite ketamine's promising results in treating depression, a significant number of patients do not respond to the treatment, and predicting who will benefit remains a challenge. Although its antidepressant effects are known to be linked to its action as an antagonist of the N-methyl-D-aspartate (NMDA) receptor, the precise mechanisms that determine why some patients respond and others do not are still unclear.
No takes yet. Share an insight, caveat, or question.
Martin et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: